We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population.
- Authors
Adamo, Vincenzo; Ricciardi, Giuseppina Rosaria Rita; Adamo, Barbara; Ferraro, Giuseppa; Franchina, Tindara; Rossello, Rosalba; Zanghì, Mariangela; Cicero, Giuseppe; Rizzo, Sergio; Caristi, Nicola; Russo, Antonio
- Abstract
Background: Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. Patients and Methods: Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). Results: Among 59 patients identified, 51 patients were evaluable (median age 76 years). The rate of any adverse event was 20% (10/51). The most relevant cardiac adverse event consisted of symptomatic congestive heart failure (CHF; n = 1, 2%) followed by asymptomatic decreases of left ventricular ejection fraction (LVEF; n = 6, 12%). Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6%). Hypertension, obesity, prior anthracyclines exposure and concurrent chemotherapy were associated with a higher incidence of toxic events. Previous radiotherapy, concurrent endocrine therapy and different trastuzumab-based regimens did not seem to influence toxicity. Conclusions: Our data suggest that trastuzumab has a good safety profile in nonfrail women aged 70 years and older. These favorable findings may be related to a limited number of anthracycline pretreatments, patient selection and a close cardiologic monitoring. © 2013 S. Karger AG, Basel
- Subjects
ITALY; ACADEMIC medical centers; ANTINEOPLASTIC agents; BREAST tumors; EPIDERMAL growth factor; HEART; MEDICAL records; ONCOGENES; PATIENT monitoring; PUBLIC health surveillance; RISK assessment; RETROSPECTIVE studies; TRASTUZUMAB; DESCRIPTIVE statistics; OLD age; THERAPEUTICS
- Publication
Oncology, 2014, Vol 86, Issue 1, p16
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000353450